BRCA1 and neoplasm: Thus, tumour samples exhibiting HRD detected on an assay for which response to PARPi has been demonstrated in clinical trials, or on one that is benchmarked to such an assay (HRD positive); for example, due to BRCA1 promoter hypermethylation or a PV in other HRR genes, are eligible for PARPi even if no PV is detected in BRCA1/2.